Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice

This publication has 48 references indexed in Scilit:

• Determination of Specific CD4 and CD8 T Cell Epitopes after AAV2- and AAV8-hF.IX Gene Therapy
  Molecular Therapy, 2006
• Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response
  Nature Medicine, 2006
• Systemic protein delivery by muscle-gene transfer is limited by a local immune response
  Blood, 2005
• Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1
  Blood, 2004
• Factors influencing cross-presentation of non-self antigens expressed from recombinant adeno-associated virus vectors
  The Journal of Gene Medicine, 2001
• Sustained Expression of Therapeutic Level of Factor IX in Hemophilia B Dogs by AAV-Mediated Gene Therapy in Liver
  Molecular Therapy, 2000
• Persistent expression of canine factor IX in hemophilia B canines
  Gene Therapy, 1999
• Haemophilia B: database of point mutations and short additions and deletions--eighth edition
  Nucleic Acids Research, 1998
• Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia
  Gene Therapy, 1998
• Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
  Nature Genetics, 1997